Ionis Pharmaceuticals, Inc.
http://www.ionispharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ionis Pharmaceuticals, Inc.
Manufacturers Eye Challenges Of Broadening Cell And Gene Therapy Access
With more advanced therapies gaining approval, companies at ARM’s Cell and Gene Meeting on the Mesa considered hurdles to making their products more broadly available and developing them for larger indications.
AstraZeneca Shows Cardiovascular Ambition With Lipoprotein Disruptor Deal
The $100m upfront deal help AZ to fill out its cardiovascular, renal and metabolism portfolio, now joining Lilly in seeking to develop an oral Lp(a)-targeting therapy.
Nxera: Building To Become Japan’s Global Biotech Champion
CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.
Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan
Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Akcea Therapeutics, Inc.
- Regulus Therapeutics, Inc.
- Symphony GenIsis, Inc.
- Isis Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice